Back grey_arrow_rt.gif
Tentative approval of emtricitabine/tenofovir
disoproxyl fumarate tablets for PEPFAR
  On December 22, 2011, FDA granted tentative approval for a fixed dose combination tablet of emtricitabine; tenofovir disoproxyl fumarate, 200 mg/300 mg. The tablet is manufactured by Hetero Labs Limited of Hyderabad, India.
"Tentative approval" means that FDA has concluded that a drug product has met all required quality, safety and efficacy standards, but is not eligible for marketing in the U.S. because of existing patent protections. Tentative approval does, however, make the product eligible for purchase outside the United States under the President's Emergency Plan for AIDS Relief program. This product was reviewed under expedited review provisions for PEPFAR.
This is a generic version of Truvada Tablets, 200 mg/300 mg, of Gilead Sciences Inc., which continues to be subject to patent protections.
Patent information is available in the FDA Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book. As with all generic applications, FDA conducts an on-site inspection of each manufacturing facility, and of the facilities performing the bioequivalence studies, to evaluate the ability of the manufacturer to produce a quality product and to assess the quality of the bioequivalence data supporting the application prior to granting approval or tentative approval to these applications.
Richard Klein Office of Special Health Issues Food and Drug Administration Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration
  icon paper stack View Older Articles   Back to Top